Canaccord Genuity Remains Bullish on ATARA Biotherapeutics (ATRA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
Cowen Starts Atara Biotherapeutics (ATRA) at Outperform
January 26, 2018 5:42 AM ESTCowen initiates coverage on Atara Biotherapeutics (NASDAQ: ATRA) with an Outperform rating.
Analyst Eric Schmidt highlights that ATRA creates novel, off-the-shelf T cell therapies for treating cancer, viral infections, and autoimmune disorders. Lead candidate tab-cel is in pivotal study for EBV+ PTLD, a... More
